Hann-Chorng Kuo, M.D.
Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University
10
10
10
N/A
0
1
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (10)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Yao-Chi Chuang, M.D.
Department of Urology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Shared therapeutic areas:
Worked with same sponsors:
Rachel Pauls, MD
TriHealth - Cincinnati Urogynecology Associates
Shared therapeutic areas:
Ho-Hsiung Lin, PhD
National Taiwan University Hospital
Shared therapeutic areas:
Chadwick Prodromos, MD
The Foundation for Orthopaedics and Regenerative Medicine
Shared therapeutic areas:
Kyu-Sung Lee, Ph.D
Samsung Medical Center
Shared therapeutic areas:
Ramon Pons
Shared therapeutic areas:
Nicolas Salvador
Shared therapeutic areas:
Mª Rosa Magallon
Shared therapeutic areas:
catherine GEINDRE
Assistance Publique Hopitaux De Marseille
Shared therapeutic areas:
Rosa Viñas
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (10)
Showing 10 of 10 trials
Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility
Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome
Urinary NGF as A Biomarker for Acute Bacterial Cystitis
Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment
Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding
Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome
Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels
Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients
All 10 trials loaded